secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aura Biosciences, Inc. (AURA)
CIK:        0001501796
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-056252
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aura Biosciences Q1 2024 net loss $19.7M; cash $202.9M funds into H2 2026
-------------------------------------------------------------------------

- Net loss of $19.7M for Q1 2024 vs $17.5M in Q1 2023; R&D spend $17.1M (up from $14.4M).
- Cash and marketable securities $202.9M as of March 31, 2024; expected to fund operations into H2 2026.
- Phase 3 CoMpass trial for small choroidal melanoma enrolling globally; target ~100 patients.
- Phase 1 bladder cancer trial enrolling; early data expected mid-2024; Fast Track designation from FDA.
- Appointed Conor Kilroy as General Counsel and Secretary.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501796/000095017024056252/0000950170-24-056252-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501796/000095017024056252/aura-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-056252

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer